Research News – Personalized Cellular Immunotherapies 

We are excited to learn that Kite Pharma announced yesterday they will initiate personalized cellular immunotherapies before the end of 2016. These therapies will target certain sub-segments of the KRAS-mutant cancer patient population (KRAS-mutations are a biomarker of colorectal cancer). This new technology will use living immune cells as the…

Read Full Post

Keeping it Brief: Immunotherapy

TOPIC OVERVIEW Immunotherapy (also known as immuno-oncology or IO) is treatment that uses certain parts of a person’s own immune system to fight diseases such as cancer. In the last few decades, it has become an important part of treating some types of cancer (including…

Read Full Post

ASCO-2016: PRE CONFERENCE INSIGHTS

The American Society of Clinical Oncology (ASCO) annual meeting happens each June in Chicago. It is one of the premier meetings each year where oncologists, scientists and advocates gather to hear the latest clinical trial data in oncology, including focused sessions on GI cancers such…

Read Full Post

CRC Immunotherapy Blueprint Presented at AACR 2016

written by Dr. Tom Marsilje, Andrea (Andi) Dwyer, Nancy Roach and Anjee Davis Last December, Fight Colorectal Cancer (Fight CRC) and the Cancer Research Institute (CRI) brought together many of the world’s leading experts on CRC and immuno-oncology. (Read more about this meeting.) The meeting goal: To…

Read Full Post

Research at Fight CRC :: March 2016 Update

This year we have really dug in and engaged in a national dialogue about colorectal cancer research. As a patient advocacy organization, we are pushing for continued progress. Our Fight CRC team, leading experts in the field, and our research advocates have been hard at…

Read Full Post

A Blueprint to Advance Colorectal Cancer (CRC) Immunotherapies

On December 2, 2015 a remarkable meeting took place. Jointly organized by Fight Colorectal Cancer and the leading immuno-oncology organization the Cancer Research Institute, an unprecedented meeting gathered many of the world’s leading experts on both CRC and immuno-oncology. Top scientists devoted to CRC research…

Read Full Post

The Future of Anti-EGFR Therapy? – Part 2

In “The Future of Anti-EGFR Therapy – Part 1” we covered some of the major ways anti-EGFR therapeutic antibodies work (“blocking the gas pedal” and “flagging the immune system”) – but there are certainly areas for improvement! Since approximately half of Stage IV colorectal cancer…

Read Full Post

The Future of anti-EGFR Therapy? – Part 1

Last month in my blogs I discussed a few completely experimental CRC drug strategies in early phase clinical trials. Drug discovery isn’t all about venturing into the complete unknown however. Identifying ways to significantly improve current therapeutic strategies that have already been proven to help…

Read Full Post

Turning a Cold CRC Tumor Hot: Part 2

In part 1 we covered the differences between “hot” and “cold” tumors. To answer the question of what is being done to help CRC patients with non-MSI tumors (the majority of CRC patients), we’ll now discuss immunotherapy concepts for these patients. A Few Experimental Strategies…

Read Full Post

Immunotherapy & Colorectal Cancer – Part 2

Yesterday in Immunotherapy for Colorectal Cancer : Part 1 we covered the basics of immunotherapy and the definitions of active and passive treatments. Today we provide insights for current research & what’s on the horizon for immunotherapy for colon and rectal cancer patients. Here’s where we are Passive immunotherapy (defined…

Read Full Post
Page 1 of 212